Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
A company with its main business in soft drinks and canned coffee might seem an unlikely entrant into the prescription pharma business, but Japan’s DyDo Group maintains it has solid reasons and a robust business plan for what it sees as an important future growth driver.
Takeda has fleshed out several aspects of its planned acquisition of Shire, emphasizing the need for speed and decisiveness if the integration is to be successful, although investors may need more reassurance ahead of required shareholder approval.
Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.